Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Thomas

Showing results (671-680 of 726) with videos related to

Pageof 73
Sort By:
Journal of Biotechnology|November 7, 2022
Impacts of fast production of afucosylated antibodies and Fc mutants in ExpiCHO-S™ for enhancing FcγRIIIa binding and NK cell activationXiaotian Zhong, Jennifer Schenk, Paul Sakorafas, et al.
Lancet (London, England)|June 17, 2014
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialEdward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2020
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Der Nervenarzt|March 14, 2024
[How the implementation of a school for people with Parkinson's disease can succeed-Results of a consensus study and a formative evaluation]Tanita Gerschel, Scally Prokop, Lara Schulze, et al.
Lung Cancer (Amsterdam, Netherlands)|March 5, 2021
Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical fieldAnna-Lena Volckmar, Petros Christopoulos, Martina Kirchner, et al.
Cancer Immunology, Immunotherapy : CII|February 17, 2019
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancerMartin Sebastian, Andreas Schröder, Birgit Scheel, et al.
Circulation. Cardiovascular Genetics|September 14, 2012
Gene-targeted analysis of copy number variants identifies 3 novel associations with coronary heart disease traitsSeán J Costelloe, Julia S El-Sayed Moustafa, Fotios Drenos, et al.
Cancer Letters|February 21, 2025
Intracellular and extracellular activities of V-domain Ig-containing suppressor of T cell activation (VISTA) modulated by immunosuppressive factors of tumour microenvironmentMaryam Abooali, Stephanie Schlichtner, Xi Lei, et al.
International Journal of Cancer|January 18, 2019
Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg casesAnna-Lena Volckmar, Jonas Leichsenring, Martina Kirchner, et al.
JCO Precision Oncology|December 5, 2025
Impact of <i>SPOP</i> Mutations on Clinical Outcomes in Metastatic Prostate CancerDeepak Kilari, Nicholas C Henderson, Kyra Yamamoto, et al.
Pageof 73

Showing results (671-680 of 726) with videos related to

Sort By:
Pageof 73
Journal of Biotechnology|November 7, 2022
Impacts of fast production of afucosylated antibodies and Fc mutants in ExpiCHO-S™ for enhancing FcγRIIIa binding and NK cell activationXiaotian Zhong, Jennifer Schenk, Paul Sakorafas, et al.
Lancet (London, England)|June 17, 2014
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialEdward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2020
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Der Nervenarzt|March 14, 2024
[How the implementation of a school for people with Parkinson's disease can succeed-Results of a consensus study and a formative evaluation]Tanita Gerschel, Scally Prokop, Lara Schulze, et al.
Lung Cancer (Amsterdam, Netherlands)|March 5, 2021
Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical fieldAnna-Lena Volckmar, Petros Christopoulos, Martina Kirchner, et al.
Cancer Immunology, Immunotherapy : CII|February 17, 2019
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancerMartin Sebastian, Andreas Schröder, Birgit Scheel, et al.
Circulation. Cardiovascular Genetics|September 14, 2012
Gene-targeted analysis of copy number variants identifies 3 novel associations with coronary heart disease traitsSeán J Costelloe, Julia S El-Sayed Moustafa, Fotios Drenos, et al.
Cancer Letters|February 21, 2025
Intracellular and extracellular activities of V-domain Ig-containing suppressor of T cell activation (VISTA) modulated by immunosuppressive factors of tumour microenvironmentMaryam Abooali, Stephanie Schlichtner, Xi Lei, et al.
International Journal of Cancer|January 18, 2019
Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg casesAnna-Lena Volckmar, Jonas Leichsenring, Martina Kirchner, et al.
JCO Precision Oncology|December 5, 2025
Impact of <i>SPOP</i> Mutations on Clinical Outcomes in Metastatic Prostate CancerDeepak Kilari, Nicholas C Henderson, Kyra Yamamoto, et al.
Pageof 73